Prevenar is one of 12 biologic programs targeting Acute otitis media. It is currently in Preclinical.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
8 competitors in Ataxia-Telangiectasia
Actos
Glucophage
N-Acetyl-L-Leucine
Nicotinamide Riboside
Prevenar
Pneumovax
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources